Literature DB >> 17320056

Central interleukin-1 (IL1) signaling is required for pharmacological, but not physiological, effects of leptin on energy balance.

Brent E Wisse1, Kayoko Ogimoto, Gregory J Morton, Diana L Williams, Michael W Schwartz.   

Abstract

Hypothalamic IL1 is suggested to be a critical mediator of the central effects of the adipocyte hormone leptin on energy balance. We hypothesized that IL1 receptor signaling is required for exogenously administered leptin to cause anorexia and weight loss, but not for physiological effects of endogenous leptin signaling on energy balance. To test this hypothesis, we investigated whether chronic hypothalamic over-expression of an IL1 receptor antagonist (AdV-IL1ra) alters food intake and weight gain in normal rats. Our findings demonstrate that impaired IL1 signaling in the CNS did not cause excess weight gain over a period of 11 days (AdV-IL1ra +38.1+/-4.1 g vs. VEH +42.2+/-5.6g; p=0.6) and caused a slightly reduced daily food intake (AdV-IL1ra 29.0+/-1.1 g/day vs. VEH 33.0+/-1.6 g/day; p<0.05). Blocking central IL1 signaling also did not alter the re-feeding response to a prolonged fast, yet was entirely effective in preventing the anorexic effect of exogenously administered leptin (2 mg/kg ip, cumulative food intake at 18 h AdV-IL1ra 30.5+/-1.1 g vs. VEH 26.4+/-1.7 g, p<0.05) and prevented leptin-induced weight loss (AdV-IL1ra -0.1+/-1.3 g vs. VEH -2.7+/-1.9 g, p<0.05). Together these findings suggest that hypothalamic IL1 signaling is required for the pharmacological effects of leptin administration, but that impaired hypothalamic IL1 signaling does not alter the physiological regulation of energy balance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17320056      PMCID: PMC2706018          DOI: 10.1016/j.brainres.2007.01.073

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  29 in total

Review 1.  Central nervous system control of food intake.

Authors:  M W Schwartz; S C Woods; D Porte; R J Seeley; D G Baskin
Journal:  Nature       Date:  2000-04-06       Impact factor: 49.962

Review 2.  CNS melanocortin system involvement in the regulation of food intake.

Authors:  S Benoit; M Schwartz; D Baskin; S C Woods; R J Seeley
Journal:  Horm Behav       Date:  2000-06       Impact factor: 3.587

3.  Central infusion of interleukin-1 receptor antagonist fails to alter feeding and weight gain.

Authors:  S Pu; H Anisman; Z Merali
Journal:  Neuroreport       Date:  2000-06-05       Impact factor: 1.837

4.  Insulin action in the brain contributes to glucose lowering during insulin treatment of diabetes.

Authors:  Richard W Gelling; Gregory J Morton; Christopher D Morrison; Kevin D Niswender; Martin G Myers; Christopher J Rhodes; Michael W Schwartz
Journal:  Cell Metab       Date:  2006-01       Impact factor: 27.287

5.  Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons.

Authors:  Gregory J Morton; Richard W Gelling; Kevin D Niswender; Christopher D Morrison; Christopher J Rhodes; Michael W Schwartz
Journal:  Cell Metab       Date:  2005-12       Impact factor: 27.287

Review 6.  The melanocortin system and energy balance.

Authors:  Andrew A Butler
Journal:  Peptides       Date:  2006-01-23       Impact factor: 3.750

Review 7.  Role of hypothalamic interleukin-1beta (IL-1beta) in regulation of energy homeostasis by melanocortins.

Authors:  Brent E Wisse; Kayoko Ogimoto; Michael W Schwartz
Journal:  Peptides       Date:  2005-11-07       Impact factor: 3.750

8.  Effect of prolonged moderate and severe energy restriction and refeeding on plasma leptin concentrations in obese women.

Authors:  B E Wisse; L A Campfield; E B Marliss; J A Morais; R Tenenbaum; R Gougeon
Journal:  Am J Clin Nutr       Date:  1999-09       Impact factor: 7.045

9.  Feeding, body weight, and sensitivity to non-ingestive reward stimuli during and after 12-day continuous central infusions of melanocortin receptor ligands.

Authors:  S Cabeza de Vaca; J Hao; T Afroz; L L Krahne; K D Carr
Journal:  Peptides       Date:  2005-11       Impact factor: 3.750

10.  Physiological regulation of hypothalamic IL-1beta gene expression by leptin and glucocorticoids: implications for energy homeostasis.

Authors:  Brent E Wisse; Kayoko Ogimoto; Gregory J Morton; Charles W Wilkinson; R Scott Frayo; David E Cummings; Michael W Schwartz
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-08-10       Impact factor: 4.310

View more
  5 in total

Review 1.  Diet, behavior and immunity across the lifespan.

Authors:  Matthew W Hale; Sarah J Spencer; Bruno Conti; Christine L Jasoni; Stephen Kent; Morgan E Radler; Teresa M Reyes; Luba Sominsky
Journal:  Neurosci Biobehav Rev       Date:  2014-12-15       Impact factor: 8.989

2.  Arcuate nucleus proopiomelanocortin neurons mediate the acute anorectic actions of leukemia inhibitory factor via gp130.

Authors:  Aaron J Grossberg; Jarrad M Scarlett; XinXia Zhu; Darren D Bowe; Ayesha K Batra; Theodore P Braun; Daniel L Marks
Journal:  Endocrinology       Date:  2009-12-16       Impact factor: 4.736

3.  Atypical protein kinase C activity in the hypothalamus is required for lipopolysaccharide-mediated sickness responses.

Authors:  Joshua P Thaler; Sun Ju Choi; Mini P Sajan; Kayoko Ogimoto; Hong T Nguyen; Miles Matsen; Stephen C Benoit; Brent E Wisse; Robert V Farese; Michael W Schwartz
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

4.  MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity.

Authors:  André Kleinridders; Dominik Schenten; A Christine Könner; Bengt F Belgardt; Jan Mauer; Tomoo Okamura; F Thomas Wunderlich; Ruslan Medzhitov; Jens C Brüning
Journal:  Cell Metab       Date:  2009-10       Impact factor: 27.287

Review 5.  Advances in deoxynivalenol toxicity mechanisms: the brain as a target.

Authors:  Marion S Bonnet; Julien Roux; Lourdes Mounien; Michel Dallaporta; Jean-Denis Troadec
Journal:  Toxins (Basel)       Date:  2012-11-01       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.